ing nerve tissue. And in January, a team of Canadian and Italian scientists working on mice announced that they were able to transform neural stem cells into blood-making bone-marrow stem cells—a process that in theory should work in human beings.
But it will take a few years for these innovations to mature, and only a pro- life minority seems willing to wait. “These are very debatable issues,” says Ronald Eastman, CEO of Geron, a California-based company that funded the Johns Hopkins and Wisconsin experiments. “But the benefits far outweigh the concerns.” Last December, Arlen Specter wondered whether embryonic-stem-cell research would create “a realistic fountain of youth.” His allies are ready to find out, even if it means bankrolling a culture of death. NR




Comments